[ad_1]
REDMOND, Wash., April 3, 2024 (GLOBE NEWSWIRE) — Pattern Computer®, Inc. (“Pattern” or the “Company”) today announced that Mark R. Anderson, Chairman and CEO, Matt Keener, CTO, and Nidhi We announced the following: Dr. Singh, Managing Director of Product Strategy/Sales, will be attending the Life Science Innovation Northwest (LSINW) 2024 Conference, April 17-18, 2024, at the Seattle Convention Center. His LSINW, hosted by Life Sciences Washington, is the Pacific Northwest’s largest annual life sciences conference, bringing together the life sciences community to discuss the most fascinating life sciences breakthroughs of our time. and will be featured. The conference will bring together CEOs, investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community.
Matt Keener will lead Pattern’s presentation, highlighting the company’s business and clinical development strategy, recent company performance, and anticipated milestones. This presentation is scheduled for Wednesday, April 17, 2024, at 1:00 PM to 3:30 PM (PT) Biotechnology Session.
Furthermore, Nidhi Singh said, “Supporting biomedical innovation through AI-powered pattern discoverywill be held in the poster presentation area (spot 11). The company will also sponsor an exhibitor’s table (table number 206), where meetings will be held for qualified institutional investors, private equity investors, and venture capital investors. For additional information or if you would like to meet with us during the conference, please contact Denyse Hudson, Pattern’s Executive Vice President of Special Projects, at denyse@patterncomputer.com.
“2024 is a transformative year for patterns,” commented Mark Anderson. “Since its inception, Pattern has followed a strategic path along a roadmap primarily focused on building the Pattern Discovery Engine™ and using it to generate high-value assets. These assets include, but are not limited to: Combination cancer drug discovery and diagnostics for the world’s top five cancers. Advances. We are looking to partner with companies to bring these drugs into clinical trials: Pattern Discovery Engine™; ProSpectral™, an innovative medical diagnostic tool and research instrument; and TrueXAI™. ”
About patterns
Pattern Computer, Inc. uses the Pattern Discovery Engine™ to solve the most important and difficult problems in business and medicine. These unique mathematical techniques in advanced AI can find complex patterns in very high-order data that would go undetected by much larger systems. The company applies its computational platform to the challenging fields of drug discovery and diagnostics, as well as at scale for partners in other sectors such as biotechnology, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and energy services. We also discover patterns. Visit www.patterncomputer.com.
contact: Laura Guerrant-Oiye (808) 960-2642 – laura@patterncomputer.com
The above contains statements regarding the future of pattern computers that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith beliefs regarding future events. The words “believe,” “expect,” “anticipate,” “predict,” “should,” “may,” “plan” and similar expressions refer to forward-looking statements. means. Forward-looking statements should not be construed as guarantees of future performance. By their nature, forward-looking statements involve inherent risks and uncertainties that change over time and may cause actual results to differ materially from those anticipated by the forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statements.
Copyright © 2024 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, PatternBio, TrueXAI, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be the trademarks of their respective owners.
[ad_2]
Source link
